Incidental uptake of fluorodeoxyglucose in the Waldeyer’s ring and risk of oropharyngeal malignancy
File(s)Bujoreanu2022_Article_IncidentalUptakeOfFluorodeoxyg.pdf (438.28 KB)
Published version
Author(s)
Bujoreanu, Iulia
Gujral, Dorothy
Wallitt, Kathryn
Awad, Zaid
Type
Journal Article
Abstract
Objective: Fluorodeoxyglucose (FDG) positron emission tomography (PET) is increasingly used to diagnose and stage malignancy. The aim of this article is to investigate the significance of incidental FDG uptake in the Waldeyer’s ring and to assess its value in predicting clinically occult oropharyngeal malignancy.
Methods: All FDG-PET/CT scans performed in Imperial College NHS Foundation Trust, UK between January 2012 and November 2018 were included. Patients with known or suspected oropharyngeal malignancy or lymphoma were excluded. Minimum follow-up was 12 months.
Results: A total of 724 scans revealed oropharyngeal uptake of FDG. Of these, 102 were included in the study. Most patients (62.1%) were scanned as part of staging for other malignancies. Oropharyngeal FDG uptake was asymmetrical in 57.3% of the cases. Uptake was more common in the tonsils (56.3%), followed by the tongue base (31.1%) and both sites (12.6%). In 41.7% of reports, appearance was described as likely physiological; however, 52.4% of reports advised direct visualisation, clinical correlation or ENT opinion. Only 24.3% (25/102) of patients were referred and seen by ENT, 14.6% (15/102) of which had an interval PET scan and 8.7% (9/102) proceeded to tissue diagnosis. There was one oropharyngeal cancer identified and one unexpected metastasis from esophageal cancer.
Conclusion: Incidental uptake on PET/CT in the oropharynx is common. However, malignancy is rare (1.9%) and, when present, is associated with high SUVmax and asymmetrical uptake. These patients should be seen by an ENT specialist yet most may not require further investigations.
Methods: All FDG-PET/CT scans performed in Imperial College NHS Foundation Trust, UK between January 2012 and November 2018 were included. Patients with known or suspected oropharyngeal malignancy or lymphoma were excluded. Minimum follow-up was 12 months.
Results: A total of 724 scans revealed oropharyngeal uptake of FDG. Of these, 102 were included in the study. Most patients (62.1%) were scanned as part of staging for other malignancies. Oropharyngeal FDG uptake was asymmetrical in 57.3% of the cases. Uptake was more common in the tonsils (56.3%), followed by the tongue base (31.1%) and both sites (12.6%). In 41.7% of reports, appearance was described as likely physiological; however, 52.4% of reports advised direct visualisation, clinical correlation or ENT opinion. Only 24.3% (25/102) of patients were referred and seen by ENT, 14.6% (15/102) of which had an interval PET scan and 8.7% (9/102) proceeded to tissue diagnosis. There was one oropharyngeal cancer identified and one unexpected metastasis from esophageal cancer.
Conclusion: Incidental uptake on PET/CT in the oropharynx is common. However, malignancy is rare (1.9%) and, when present, is associated with high SUVmax and asymmetrical uptake. These patients should be seen by an ENT specialist yet most may not require further investigations.
Date Issued
2021-09-27
Date Acceptance
2020-12-29
Citation
Oncology: international journal of cancer research and treatment, 2021, 279, pp.2657-2664
ISSN
0030-2414
Publisher
Karger Publishers
Start Page
2657
End Page
2664
Journal / Book Title
Oncology: international journal of cancer research and treatment
Volume
279
Copyright Statement
© Crown 2021. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
License URL
Identifier
https://link.springer.com/article/10.1007/s00405-021-07089-6
Subjects
Science & Technology
Life Sciences & Biomedicine
Otorhinolaryngology
Head and neck
Positron emission tomography
Oropharynx
Head and neck cancer
POSITRON-EMISSION-TOMOGRAPHY
SQUAMOUS-CELL CARCINOMA
STANDARDIZED UPTAKE
COMPUTED-TOMOGRAPHY
F-18-FDG PET/CT
UPTAKE VALUES
NECK-CANCER
FDG-PET/CT
HEAD
DIFFERENTIATION
Head and neck
Head and neck cancer
Oropharynx
Positron emission tomography
Fluorodeoxyglucose F18
Humans
Incidental Findings
Neoplasms, Unknown Primary
Oropharyngeal Neoplasms
Positron Emission Tomography Computed Tomography
Positron-Emission Tomography
Radiopharmaceuticals
Retrospective Studies
Humans
Oropharyngeal Neoplasms
Neoplasms, Unknown Primary
Fluorodeoxyglucose F18
Radiopharmaceuticals
Positron-Emission Tomography
Incidental Findings
Retrospective Studies
Positron Emission Tomography Computed Tomography
1103 Clinical Sciences
Otorhinolaryngology
Publication Status
Published
Date Publish Online
2021-09-27